Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BAT7104

Phase 3Biologic

BAT7104 is one of 37 biologic programs targeting Migraine. It is currently in Phase 3.

1

Indications

2

Total Trials

1

Active Trials

36

Competitors

Pipeline

Status by Indication[3][1]

Indication

MigraineActive, not recruiting

MigrainePhase 3

Active, not recruiting

Competition

Competitive Landscape

105 competitors in Migraine

#DrugCompanyPhaseTrials

Zonegran

AAzurity Pharmaceuticals

Avicel

SSanthera Pharmaceuticals

Magnesium

SSpherium Biomed

Elismetrep

Flunarizine

AAspartes Pharmaceuticals, Inc.

BAT7104

Bayer Aspirin

Cymbalta

Jazz Pharmaceuticals

Adempas

Cervidil

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced Malignant Tumors1 trial

BAT7104 Injection in Patients With Advanced Malignant Tumors.

Completed·BBio-Thera Solutions·Phase 1·NCT05767060·86 enrolled

Migraine1 trial

HARMONY: Fremanezumab Preventive in Episodic Migraine

Active, not recruiting· Teva logo

Teva·Phase 3·NCT05200013·650 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BAT7104. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BAT7104 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BAT7104. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Teva

Related News